Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of apixaban vs LMWH/fondaparinux plus VKA in acute symptomatic DVT
2005-001388-71Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of apixaban in deep vein thrombosis (DVT) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Efficacy of apixaban vs conventional therapy and Safety of apixaban vs conventional therapy. Started Aug 2005; status: completed.
02
Drugs
apixaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2005-001388-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001388-71.